Welcome to RealPatient FL

RealPatient is your self-guided tour through published sources of CAR‑T real-world evidence and clinical trial data.

Select patient profiles of interest and view relevant real-world outcomes and clinical data. Latest data sources are updated regularly.

Disclaimer: This resource is an educational application only for worldwide healthcare professionals. It includes publicly available CAR‑T real-world evidence from large international and national registries and pivotal clinical trials. Reactive use only. Intended for HCPs.

Who is your CAR‑T patient?

Start now

Tisagenlecleucel ▼ is a CD19-directed genetically modified autologous T-cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy.¹

Reference: 1. Kymriah [summary of product characteristics]. Nuremberg, Germany: Novartis Pharma GmbH; 2024.

5/24 434310